Document Detail


Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease.
MedLine Citation:
PMID:  22761074     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Purpose The evidence evaluating the efficacy of i.v. versus oral iron for the treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease (CKD) is reviewed. Summary Although erythropoiesis-stimulating agents (ESAs) are the mainstay of anemia treatment, concomitant iron supplementation is often required. Patients with CKD are at risk for developing iron deficiency due to frequent blood testing, decreased dietary intake, inflammation, decreased gastrointestinal absorption, the use of phosphate binders, hemodialysis, and treatment with ESAs. Seven randomized, controlled trials compared i.v. and oral iron in this population, six in patients treated with ESAs and one in patients not receiving ESAs. Two studies found no difference between i.v. and oral iron. An additional study found the two formulations to be equivalent when evaluating ESA dosage requirements. All studies found i.v. iron to be superior in increasing ferritin and transferrin saturation (TSAT) levels. Five of the studies compared baseline laboratory values for patients treated with i.v. and oral iron; all of these found oral iron to significantly increase hemoglobin, ferritin, or TSAT levels. Only one trial found a significant decrease from baseline in ferritin and TSAT for oral iron. Interpretation of the results of these studies is limited by several factors, the most significant of which is a short study duration, ranging from 21 days to six months. Conclusion Published evidence does not support the use of i.v. iron over oral iron to treat deficiencies in non-hemodialysis-dependent patients with CKD. While studies found that i.v. iron significantly increased serum levels of ferritin and TSAT, hemoglobin levels were not consistently raised.
Authors:
Anne Marie Liles
Related Documents :
22412904 - Non-coding keratin variants associate with liver fibrosis progression in patients with ...
1741604 - A five-year analysis of botulinum toxin type a injections: some unusual features.
2263874 - Effect of transcutaneous nerve stimulation on esophageal motility in patients with acha...
9747164 - Manometric findings of the upper esophageal sphincter in esophageal achalasia.
12464984 - Increased p wave dispersion: a new finding in patients with syndrome x.
24025644 - Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in pati...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  69     ISSN:  1535-2900     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-07-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1206-11     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Critical illness polyneuromyopathy.
Next Document:  Comparison of intravenous and oral magnesium replacement in hospitalized patients with cardiovascula...